146 related articles for article (PubMed ID: 18457384)
1. Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.
Hassani M; Cai W; Koelsch KH; Holley DC; Rose AS; Olang F; Lineswala JP; Holloway WG; Gerdes JM; Behforouz M; Beall HD
J Med Chem; 2008 Jun; 51(11):3104-15. PubMed ID: 18457384
[TBL] [Abstract][Full Text] [Related]
2. Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.
Hassani M; Cai W; Holley DC; Lineswala JP; Maharjan BR; Ebrahimian GR; Seradj H; Stocksdale MG; Mohammadi F; Marvin CC; Gerdes JM; Beall HD; Behforouz M
J Med Chem; 2005 Dec; 48(24):7733-49. PubMed ID: 16302813
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents.
Cai W; Hassani M; Karki R; Walter ED; Koelsch KH; Seradj H; Lineswala JP; Mirzaei H; York JS; Olang F; Sedighi M; Lucas JS; Eads TJ; Rose AS; Charkhzarrin S; Hermann NG; Beall HD; Behforouz M
Bioorg Med Chem; 2010 Mar; 18(5):1899-909. PubMed ID: 20149966
[TBL] [Abstract][Full Text] [Related]
4. COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates.
Fagan V; Bonham S; Carty MP; Saenz-Méndez P; Eriksson LA; Aldabbagh F
Bioorg Med Chem; 2012 May; 20(10):3223-32. PubMed ID: 22522008
[TBL] [Abstract][Full Text] [Related]
5. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
Fryatt T; Pettersson HI; Gardipee WT; Bray KC; Green SJ; Slawin AM; Beall HD; Moody CJ
Bioorg Med Chem; 2004 Apr; 12(7):1667-87. PubMed ID: 15028260
[TBL] [Abstract][Full Text] [Related]
6. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
7. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
[TBL] [Abstract][Full Text] [Related]
8. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q
Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653
[TBL] [Abstract][Full Text] [Related]
9. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
[TBL] [Abstract][Full Text] [Related]
10. Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.
Newsome JJ; Swann E; Hassani M; Bray KC; Slawin AM; Beall HD; Moody CJ
Org Biomol Chem; 2007 May; 5(10):1629-40. PubMed ID: 17571194
[TBL] [Abstract][Full Text] [Related]
11. Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
Kadela-Tomanek M; Jastrzębska M; Pawełczak B; Bębenek E; Chrobak E; Latocha M; Książek M; Kusz J; Boryczka S
Eur J Med Chem; 2017 Jan; 126():969-982. PubMed ID: 28006669
[TBL] [Abstract][Full Text] [Related]
12. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
Colucci MA; Moody CJ; Couch GD
Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
[TBL] [Abstract][Full Text] [Related]
13. Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
Kadela-Tomanek M; Bębenek E; Chrobak E; Marciniec K; Latocha M; Kuśmierz D; Jastrzębska M; Boryczka S
Eur J Med Chem; 2019 Sep; 177():302-315. PubMed ID: 31158746
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
Bian J; Xu L; Deng B; Qian X; Fan J; Yang X; Liu F; Xu X; Guo X; Li X; Sun H; You Q; Zhang X
Bioorg Med Chem Lett; 2015 Mar; 25(6):1244-8. PubMed ID: 25677663
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of new quinolinequinone derivatives and preliminary exploration of their cytotoxic properties.
Keyari CM; Kearns AK; Duncan NS; Eickholt EA; Abbott G; Beall HD; Diaz P
J Med Chem; 2013 May; 56(10):3806-19. PubMed ID: 23574193
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of antitumor activity of novel N-acyllavendamycin analogues and quinoline-5,8-diones.
Behforouz M; Cai W; Mohammadi F; Stocksdale MG; Gu Z; Ahmadian M; Baty DE; Etling MR; Al-Anzi CH; Swiftney TM; Tanzer LR; Merriman RL; Behforouz NC
Bioorg Med Chem; 2007 Jan; 15(1):495-510. PubMed ID: 17035024
[TBL] [Abstract][Full Text] [Related]
17. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
18. Functionalized 3-benzylidene-indolin-2-ones: inducers of NAD(P)H-quinone oxidoreductase 1 (NQO1) with antiproliferative activity.
Zhang W; Go ML
Bioorg Med Chem; 2009 Mar; 17(5):2077-90. PubMed ID: 19200740
[TBL] [Abstract][Full Text] [Related]
19. Total synthesis of novel 6-substituted lavendamycin antitumor agents.
Seradj H; Cai W; Erasga NO; Chenault DV; Knuckles KA; Ragains JR; Behforouz M
Org Lett; 2004 Feb; 6(4):473-6. PubMed ID: 14961601
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
